The estimated Net Worth of Federico A. Tripodi is at least 1.43 百万$ dollars as of 15 June 2018. Federico Tripodi owns over 14,700 units of Calyxt Inc stock worth over 1,142,190$ and over the last 6 years Federico sold CLXT stock worth over 286,503$.
Sign up
Federico Tripodi CLXT stock SEC Form 4 insiders trading
Federico has made over 1 trades of the Calyxt Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Federico sold 14,700 units of CLXT stock worth 286,503$ on 15 June 2018.
The largest trade Federico's ever made was selling 14,700 units of Calyxt Inc stock on 15 June 2018 worth over 286,503$. On average, Federico trades about 14,700 units every 0 days since 2018. As of 15 June 2018 Federico still owns at least 181,300 units of Calyxt Inc stock.
You can see the complete history of Federico Tripodi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Federico Tripodi's mailing address?
Federico's mailing address filed with the SEC is 600 County Rd D West #8, New Brighton, MN 55112, USA.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over 2,578,214$ worth of Calyxt Inc stock and bought 116,475 units worth 1,447,167$ . The most active insiders traders include Kimberly K. Nelson、Daniel F Voytas、Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of 35,853$. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth 7,200$.
What does Calyxt Inc's logo look like?
Complete history of Federico Tripodi stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner